Short answer
Adicet Bio Inc (ACET) filed its Q3 2019 10-Q quarterly report on Nov 5, 2019 for the quarter ended Sep 30, 2019.
Adicet Bio Inc Q3 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales generated
- Operating margin not applicable, operating loss $25.2M vs $9.0M YoY
- R&D highest spending area, $22.1M vs $6.8M, driven by Phase 3 trials
- Cash, equivalents and marketable securities $117.3M; operating cash use $48.0M
- PROTECTOR 1 enrollment complete at 1,024 patients, data expected early 2020; funding projected through 2020
Risk Factors
- No material changes to 10-K risk factors for year ended December 31, 2018
- Clinical development risk: forward-looking assumptions involve circumstances largely outside management’s control
- Company-specific risk: filing identifies issuer as resTORbio, despite user-provided Adicet Bio designation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adicet Bio Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.